Solvonis Therapeutics (LSE:SVNS) reported cash and cash equivalents of £1.720 million at the year ended 31 December 2025, a position the company says is expected to provide funding through to the end of 2026.
The year saw a strategic transformation through the acquisition of Awakn Life Sciences, a change of name and a refocus as an emerging biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system disorders with an initial focus on addiction and psychiatry.
The pipeline is led by SVN-001, now in Phase 3 for severe Alcohol Use Disorder in the UK, alongside SVN-002 in Phase 2 planning for moderate-to-severe AUD in the U.S., and an AI-enabled discovery platform producing candidates including SVN-114 (PTSD) and SVN-015, which was accepted into the NIDA programme.
The Board says a changed U.S. Regulatory and market backdrop, including an executive order accelerating psychedelic research, early FDA priority voucher awards and strategic M&A in the space, supports its view that greater shareholder value may be available at or after successful Phase 3 completion than from an earlier out-licence.
The Board notes it has held several positive discussions with potential partners but will prioritise advancing SVN-001 through to the Phase 3 value inflection point while retaining strategic flexibility.
"The Board believes Solvonis now has a stronger portfolio, a clearer strategic position and a more compelling opportunity set than at any point in its recent history," said Dennis Purcell, Non‑Executive Chairman.
